ArticleInternational wound journal2026
Use of a Synthetic Polylactic Acid Matrix for Pyoderma Gangrenosum: A Case Series.
Article in International wound journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pyoderma gangrenosum (PG) is a rare chronic neutrophilic dermatosis closely associated with immune dysregulation and characterized by painful, treatment-resistant ulcers. Currently, no standardized therapeutic protocol exists; however, topical and systemic immune-modulating therapies have shown positive results. In this article, we evaluate the use of polylactic acid (PLA) matrices as a treatment option, given their immunomodulatory properties and beneficial effects on complex wounds. This case series presents six patients (ages 38-72, five female and one male) with chronic, non-healing ulcers that persisted for 6 months to 3 years previous to the treatment described. PLA matrices were used as the primary wound treatment, requiring a mean of 5.3 applications for healing. Wound closure was achieved in all cases within a mean time of 13.4 weeks with successful outcomes in both scar quality and appearance. PLA matrices may represent a promising local treatment option for PG ulcers; however, these preliminary findings require confirmation in larger, controlled studies.
Indexed as
Identifiers
42823925What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.